| Id: | acc4710 |
| Group: | 1sens |
| Protein: | Smad2 |
| Gene Symbol: | SMAD2 |
| Protein Id: | Q15796 |
| Protein Name: | SMAD2_HUMAN |
| PTM: | phosphorylation |
| Site: | unclear |
| Site Sequence: | |
| Disease Category: | Respiratory system diseases |
| Disease: | Pulmonary Fibrosis |
| Disease Subtype: | Idiopathic Pulmonary Fibrosis |
| Disease Cellline: | NHLF、DHLF、LL29 |
| Disease Info: | |
| Drug: | Biochanin-A(BCA) |
| Drug Info: | Biochanin-A (BCA) is a natural isoflavone with potential health - promoting properties. It may have beneficial effects on various physiological functions. |
| Effect: | inhibit |
| Effect Info: | BCA treatment can significantly inhibit the phosphorylation levels of TGF-beta and its downstream Smad2/3 proteins in lung tissues and alleviate the pathological abnormalities of lung tissues induced by BLM. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 32781391 |
| Sentence Index: | 32781391_13 |
| Sentence: | "In addition, BCA treatment significantly (p < 0.001) attenuated the TGF-beta1/BLM-mediated increase of TGF-beta/Smad2/3 phosphorylation and resulted in the reduction of pathological abnormalities in lung tissues determined by histopathology observations." |
Sequence & Structure:
MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTPNTIDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| SMAD2-Ser118 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -1.1 | ||||
| HGSC | |||||
| ccRCC | 0.246 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 0.854 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| SMAD2-Thr172 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.002 |
| COAD | -0.816 |
| HGSC | 1.954 |
| ccRCC | -0.467 |
| GBM | |
| HNSC | -0.115 |
| LUAD | -0.6 |
| LUSC | 0.334 |
| non_ccRCC | -1.011 |
| PDAC | -0.765 |
| UCEC | 1.485 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | A | Salivary adenoid cystic carcinoma | Phosphorylation | 21441221 |
| - | - | D | Hepatocellular carcinoma | Ubiquitination | 35509688 |
| - | - | P | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 24334458 |
| - | - | P | Pre-eclampsia | Phosphorylation | 22832245 |
| - | - | P | Gastric cancer | Ubiquitination | 32226309 |
| - | - | U | Ovarian cancer | Phosphorylation | 35293014 |
| - | - | U | Breast cancer | Ubiquitination | 33649832 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
